Eli Lilly Announces 2013 Financial Guidance
Eli Lilly expects overall revenue growth in the coming year.
Eli Lilly expects overall revenue growth in 2013 with anticipated revenue between $22.6 and $23.4 billion, according to a Jan. 4, 2013 press release, which announced the company’s 2013 financial guidance. The company expects full-year 2013 earnings per share to be in the range of $4.03 to $4.18 on a reported basis. Earnings per share would be $3.75 to $3.90 on a non-GAAP basis when excluding an estimated $0.28 per share of exenatide-related income contingent upon the transfer of exenatide commercial rights outside the US to Amylin, notes the company.
This guidance excludes the one-time impact of the tax benefit from the American Taxpayer Relief Act of 2012, which relates to 2012 financial results but will be reflected in the 2013 results because the Act was not officially enacted until 2013.
"We remain on track to meet or exceed our minimum financial performance targets,” said Derica Rice, Lilly executive vice president, global services, and chief financial officer, in the press release. “From now through 2014, on an annual basis we still expect revenue to be at least $20 billion, net income to be at least $3 billion, and operating cash flow to be at least $4 billion."
The company seeks to bridge a period of patent expirations and return to sustainable growth. "We are replenishing and advancing our pipeline, which now has 13 potential new medicines in Phase III testing,” said John C. Lechleiter, PhD, Lilly's chairman, president and chief executive officer, in the press release. “We are investing to drive growth in key currently marketed brands and in our counter-cyclical growth areas, and we continue to make productivity gains across our business to fund the R&D necessary to fuel our future growth, recapitalize our physical assets, maintain our dividend, and support our share repurchase program.”
The company expects total operating expenses in 2013 to be flat or slightly less than 2012 as a result of continued expense controls and productivity gains. Marketing, selling, and administrative expenses are expected in the range of $7.1 billion to $7.4 billion, and R&D expenses are expected to be in the range of $5.2 billion to $5.5 billion.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
